Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.

about

Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.

Item

http://www.wikidata.org/entity/Q38347765

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Oritavancin, a single-dose, co ...... and skin structure infections.

@en

type

Item

label

Oritavancin, a single-dose, co ...... and skin structure infections.

@en

prefLabel

Oritavancin, a single-dose, co ...... and skin structure infections.

@en

P1476

Oritavancin, a single-dose, co ...... and skin structure infections

@en

P2093

Anh Wu

http://www.w3.org/2001/XMLSchema#string

Gary Wu

http://www.w3.org/2001/XMLSchema#string

James Truong

http://www.w3.org/2001/XMLSchema#string

Mei Liu

http://www.w3.org/2001/XMLSchema#string

Ola Elnadoury

http://www.w3.org/2001/XMLSchema#string

Spencer Lee

http://www.w3.org/2001/XMLSchema#string

Teena Abraham

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.

Trends in US hospital admissions for skin and soft tissue infections

In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers.

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.

Oritavancin: mechanism of action.

Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.

Hospitalist perspective on the treatment of skin and soft tissue infections.

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

P304

409-416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.2015.1012498

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William Kuan

P577

2015-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25661747

http://www.w3.org/2001/XMLSchema#string